儿童成纤维细胞生长因子23轨迹与CKD进展的关联:CKiD研究
该研究在543例CKD 2-4期儿童中每半年检测一次C端FGF23与eGFR,中位观察4年。多数患儿FGF23轨迹稳定,快速上升组eGFR更低、血磷更高、蛋白尿更多且贫血更重;校正后缓慢上升组和快速上升组进展至肾衰竭的风险分别高出1.7倍和8倍。
要点
- 儿童CKD中多数FGF23水平稳定,仅少数呈快速上升轨迹
- FGF23上升越快,基线eGFR越低、血磷越高、蛋白尿与贫血越重
- FGF23轨迹可独立预测儿童CKD进展至肾衰竭的风险
核心结论
- 在儿童CKD中FGF23多数保持稳定,但上升较快的轨迹组与进展至肾衰竭风险升高独立相关。
研究设计与样本
- CKiD队列中543例CKD 2-4期儿童,每半年测C端FGF23与eGFR,每人2-3次FGF23检测,采用线性混合模型与潜在轨迹模型分析,并用Cox模型评估肾衰竭风险。
主要发现
- 入组中位年龄12岁、eGFR 52 ml/min per 1.73 m²,中位观察4年,FGF23年均升高3.7%、eGFR年均下降3.8%。
- 轨迹分为稳定组64%(斜率0%/年)、缓慢上升组30%(6%/年)、快速上升组6%(39%/年)。
- 上升较快的轨迹组eGFR更低、血磷更高、蛋白尿更多并伴贫血。
- 中位随访4.9年,全校正后缓慢上升组肾衰竭风险高1.7倍(95%CI 1.09-2.67),快速上升组高8倍(95%CI 2.41-23.56)。
- 校正模型中血磷z评分轨迹与进展至肾衰竭无关联。
关键数值与推荐
- FGF23轨迹分组:稳定64%、缓慢上升30%、快速上升6%。
- 肾衰竭风险:缓慢上升组HR 1.7(95%CI 1.09-2.67),快速上升组HR 8(95%CI 2.41-23.56),均与稳定组比较。
临床怎么用
- 对儿童CKD患者可考虑纵向监测FGF23,结合轨迹判断肾衰竭进展风险。
局限性
- FGF23与CKD进展是因果还是结果尚不明确,需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
KEY POINTS: In a large longitudinal study of predialysis CKD, plasma fibroblast growth factor 23 was stable in most of the children when modeled as linear trajectories over time Children with rapidly rising fibroblast growth factor 23 trajectories exhibited lower eGFR, higher serum phosphorus, proteinuria, and anemia compared with those with stable levels Longitudinal fibroblast growth factor 23 monitoring provides a powerful, independent predictor of kidney disease progression in children with CKD. BACKGROUND: In children and adults, plasma fibroblast growth factor 23 (FGF23) concentrations increase early in CKD and associate with disease progression and adverse cardiovascular outcomes. However, longitudinal changes in FGF23 in children with progressive CKD are not well characterized. METHODS: We measured c -terminal FGF23 biannually and eGFR in 543 children with CKD stages 2-4 enrolled in the CKD in children study. All participants had 2-3 FGF23 measurements. We used a linear mixed model to estimate the average percent change in FGF23 and eGFR over time for the overall cohort and latent group-based trajectory modeling to identify populations with distinct patterns of change in FGF23 concentration, eGFR, and phosphorus z -score. We used Cox proportional hazards model to examine the risk of progression to kidney failure according to FGF23 trajectory group. RESULTS: At study enrollment, the median age was 12 years and eGFR 52 ml/min per 1.73 m 2 . In univariate models with repeated measures, FGF23 increased by a mean of 3.7% annually, and eGFR decreased by 3.8% annually over a median observation period of 4 years. We identified three distinct FGF23 trajectories: stable in 64% of participants (FGF23 slope 0% per year); slowly rising in 30% (slope 6% per year) and rapidly rising in 6% (slope 39% per year). Membership in the faster-rising trajectory groups was associated with lower eGFR, higher serum phosphorus, greater proteinuria, and anemia. With subsequent median 4.9 years of follow-up, the risk of kidney failure was 1.7-fold higher (95% confidence interval, 1.09 to 2.67) in the slowly rising and 8-fold higher (95% confidence interval, 2.41 to 23.56) in the rapidly rising FGF23 trajectory group compared with the stable trajectory group, in fully adjusted analyses. Phosphorus z -score trajectories did not associate with progression to kidney failure in adjusted models. CONCLUSION: By characterizing longitudinal changes in FGF23 in children with CKD, we find that FGF23 was stable in most children. Membership in the faster-rising FGF23 trajectory groups associates with increased risk of progression to kidney failure. Future studies are needed to investigate whether FGF23 is a modifiable cause or a consequence of CKD progression in children with CKD.
引用
- Perwad F, Matheson MB, Glenn Lecea E, et al. Fibroblast Growth Factor 23 Trajectories in Children and Association with CKD Progression: The CKD in Children Study. Clin J Am Soc Nephrol. 2026. PMID: 41642661. doi:10.2215/CJN.0000000954
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。